The clinical course and prognosis of patients with renal adenocarcinoma with solitary metastasis.
The present investigation describes a series of 25 patients with solitary metastasis from a renal adenocarcinoma. Forty-eight percent of the patients had metastatic foci in bones, 24% in the lungs, and 28% in a variety of organs. Radiotherapy was the treatment for 64% of the patients, surgery for 36%. Disease control after treatment was obtained in 88% of the patients. The 5-year survival rate was 39%. Sixteen of 25 patients died after a mean survival time of 36 months; 9/25 patients are still living 28-126 months after treatment. Women survived significantly better than men. Patients with normal pre- and post-treatment erythrocyte sedimentation rate (ESR) survived significantly longer than patients with elevated ESR. A definite relationship between ESR and disease activity was demonstrated in 64% of the patients. We concluded that solitary metastases in bones can be treated with radiotherapy; even if 64% of the patients die there is significant clinical remission to be obtained after aggressive treatment. Furthermore, ESR seems to be an important indicator of prognosis and disease activity.
D000230:Adenocarcinoma / Q000097:blood / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D001799:Blood Sedimentation; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary* / Q000628:therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood / Q000628:therapy*; D008175:Lung Neoplasms / Q000097:blood / Q000556:secondary* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis